NASDAQ:VIVE - Viveve Medical Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.20 +0.04 (+3.45 %)
(As of 01/21/2019 12:45 PM ET)
Previous Close$1.16
Today's Range$1.17 - $1.25
52-Week Range$0.93 - $4.93
Volume254,517 shs
Average Volume245,224 shs
Market Capitalization$37.85 million
P/E Ratio-0.57
Dividend YieldN/A
Beta0.62
Viveve Medical, Inc. designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency generator, a reusable hand piece, and single-use treatment tip, as well as other consumable accessories. It markets its products through sales employees and distributors in the United States, the Asia Pacific, Europe, the Middle East, Latin America, and Canada. Viveve Medical, Inc. was founded in 2005 and is headquartered in Englewood, Colorado.

Receive VIVE News and Ratings via Email

Sign-up to receive the latest news and ratings for VIVE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VIVE
Previous SymbolOTCMKTS:PLCSD
CUSIPN/A
Phone720-696-8100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15.29 million
Book Value($0.13) per share

Profitability

Net Income$-36,950,000.00
Net Margins-243.98%

Miscellaneous

Employees103
Market Cap$37.85 million
OptionableOptionable

Viveve Medical (NASDAQ:VIVE) Frequently Asked Questions

What is Viveve Medical's stock symbol?

Viveve Medical trades on the NASDAQ under the ticker symbol "VIVE."

How were Viveve Medical's earnings last quarter?

Viveve Medical Inc (NASDAQ:VIVE) posted its earnings results on Friday, November, 9th. The company reported ($0.39) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.33) by $0.06. The company earned $4.82 million during the quarter, compared to analyst estimates of $4.60 million. Viveve Medical had a negative net margin of 243.98% and a negative return on equity of 838.28%. View Viveve Medical's Earnings History.

When is Viveve Medical's next earnings date?

Viveve Medical is scheduled to release their next quarterly earnings announcement on Thursday, March 21st 2019. View Earnings Estimates for Viveve Medical.

What guidance has Viveve Medical issued on next quarter's earnings?

Viveve Medical issued an update on its FY 2019 earnings guidance on Wednesday, January, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $20-20 million, compared to the consensus revenue estimate of $22.2 million.Viveve Medical also updated its FY 2018 guidance to EPS.

What price target have analysts set for VIVE?

5 Wall Street analysts have issued 1-year price targets for Viveve Medical's stock. Their forecasts range from $3.00 to $11.00. On average, they expect Viveve Medical's share price to reach $7.50 in the next year. This suggests a possible upside of 525.0% from the stock's current price. View Analyst Price Targets for Viveve Medical.

What is the consensus analysts' recommendation for Viveve Medical?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viveve Medical in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Viveve Medical.

What are Wall Street analysts saying about Viveve Medical stock?

Here are some recent quotes from research analysts about Viveve Medical stock:
  • 1. Maxim Group analysts commented, "Market open, VIVE reported preliminary 4Q18 revenue that was slightly above both our estimate and consensus. However, the company also introduced full-year 2019 revenue guidance that was slightly below both our estimate and consensus. VIVE announced a strategic restructuring that is expected to reduce its workforce by 36% in order to decrease operating costs. Based on its recent capital raise and strategic realignment plan, we believe VIVE has sufficient cash to fund operations through 1Q20. The company plans to report full 4Q18 results in March 2019." (1/17/2019)
  • 2. Mizuho analysts commented, "We expect the trends in utilization and pricing to continue in 2018. FDA Approval of IDE to Conduct VIVEVE2 Clinical Trial. The FDA approved Viveve’s IDE to conduct a sexual function study in the U.S. The study is expected to start in 2Q18 and will include approximately 250 patients across 25 clinical sites in the U.S. and Canada. The primary endpoint will measure the mean change from baseline in the total FSFI (Female Sexual Function Index) at 12 months. Data from the study is expected in 2H19. Cash Position and Upcoming Catalysts. Viveve’s current cash position stands at approximately $55.7 mil following a recent $35.0 mil equity offering in February." (3/20/2018)

Has Viveve Medical been receiving favorable news coverage?

Media stories about VIVE stock have been trending positive this week, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Viveve Medical earned a media sentiment score of 2.7 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days.

Who are some of Viveve Medical's key competitors?

Who are Viveve Medical's key executives?

Viveve Medical's management team includes the folowing people:
  • Mr. Scott C. Durbin, CEO & Director (Age 50)
  • Mr. James Gregory Atkinson, Chief Bus. Officer & Pres (Age 61)
  • Ms. Deborah A. Jorn, Sr. Advisor to the CEO & Director (Age 61)
  • Mr. Jim B. Robbins, VP of Fin. & Admin., Principal Accounting Officer & Principal Financial Officer (Age 55)
  • Mr. Martin Kerber, VP of Operations

When did Viveve Medical IPO?

(VIVE) raised $13 million in an initial public offering on Tuesday, June 14th 2016. The company issued 1,600,000 shares at $8.00 per share. Ladenburg Thalmann and Craig-Hallum Capital Group served as the underwriters for the IPO and Maxim Group was co-manager.

How do I buy shares of Viveve Medical?

Shares of VIVE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Viveve Medical's stock price today?

One share of VIVE stock can currently be purchased for approximately $1.20.

How big of a company is Viveve Medical?

Viveve Medical has a market capitalization of $37.85 million and generates $15.29 million in revenue each year. The company earns $-36,950,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Viveve Medical employs 103 workers across the globe.

What is Viveve Medical's official website?

The official website for Viveve Medical is http://www.viveve.com.

How can I contact Viveve Medical?

Viveve Medical's mailing address is 345 INVERNESS DRIVE SOUTH BUILDING B SUITE 250, ENGLEWOOD CO, 80112. The company can be reached via phone at 720-696-8100 or via email at [email protected]


MarketBeat Community Rating for Viveve Medical (NASDAQ VIVE)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  197 (Vote Outperform)
Underperform Votes:  106 (Vote Underperform)
Total Votes:  303
MarketBeat's community ratings are surveys of what our community members think about Viveve Medical and other stocks. Vote "Outperform" if you believe VIVE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VIVE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel